tolvaptan has been researched along with Sarcopenia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Aikata, H; Chayama, K; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kodama, K; Morio, K; Murakami, E; Nakahara, T; Namba, M; Ohya, K; Tsuge, M; Uchikawa, S; Yamauchi, M | 1 |
1 other study(ies) available for tolvaptan and Sarcopenia
Article | Year |
---|---|
Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Female; Follow-Up Studies; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Muscle, Skeletal; Organ Size; Prognosis; Retreatment; Retrospective Studies; Sarcopenia; Survival Rate; Time Factors; Tolvaptan; Tomography, X-Ray Computed; Young Adult | 2020 |